Projekt

First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial

Laufend - Rekrutierung – beendet · 2018 bis 2099

Früh Martin, Breuss Kim, Quinter Janine